medigraphic.com
ISSN 0188-9796 (Print)

2001, Number 2

<< Back Next >>

Rev Endocrinol Nutr 2001; 9 (2)

Obesity as risk factor of coronary heart disease in personnel of the Hospital General de México. PRIT study

Fanghänel G, Sánchez-Reyes L, Gómez SR, Torres AE, Berber A

Language: Spanish
References: 38
Page: 51-59
PDF size: 185.96 Kb.


ABSTRACT

Objective: To evaluate the prevalence of obesity and its relationship with risk factors in coronary heart disease in the personnel of the General Hospital in Mexico City. Material and methods: We study 3,801 workers, 1,147 male (30.2%) and 2,654 female (69.8%), from 16 to 65 years old, they were divided in 5 groups according body mass index (kg/m2): 1) normal range ‹ 25; 2) pre-obese 26 to 26.9; 3) mild obesity 27 to 29.9; 4) moderate obesity 30 to 34.9 and 5) severe obesity 35 or more. We realized clinical history, anthropometric measures, and laboratory determinations of glucose, total cholesterol, c-LDL, c-HDL and triglycerides. Results: The mean age for female were 38.5 and for males 39.0 years. The prevalence (%) in by body mass index levels for males and female were: 1) 52.7, 47.9; 2) 18.8, 18.3; 3) 15.2, 18.1; 4) 12.3, 13.1 and 5) 1.0, 2.7. The prevalence of high waist circumference (males › 102 cm and female › 88 cm) were: 1) 0.0, 0.23; 2) 0.0, 1.4; 3) 1.14, 11.6; 4) 15.6, 31.9 and 5) 27.2, 50.0. Coronary risk factors (%) for each group and for sex were: HTA 1) 5.4, 7.0; 2) 21.2, 16.9; 3) 29.8, 23.9; 4) 39.0, 37.1 and 5) 63.6, 47.2. Type-2 DM: 1) 5.4, 5.6; 2) 5.5, 5.1; 3) 8.0, 8.9; 4) 13.4, 13.8 and 5) 18.1, 16.6. Hypercholesterolemia (› 240 mg/dL): 1) 13.2, 12.9; 2) 21.7, 19.5; 3) 29.8, 22.0; 4) 25.5, 33.4 and 5) 27.2, 20.8. hypertriglyceridemia (› 200 mg/dL): 1) 20.1, 14.2; 2) 28.7, 20.2; 3) 37.3, 26.0; 4) 37.7, 38.6 and 5) 54.5, 41.6. Smoking was positive in: 1) 33.5, 25.8; 2) 52.7, 36.9; 3) 54.0, 33.7; 4) 60.9, 33.7 and 5) 36.3, 25.0. Conclusions: In this study we confirmed the high prevalence of risk factors in coronary heart disease in personnel of the General Hospital in Mexico City with obesity, in most cases risk factors that can be modified, and therefore the possibility of realize preventive actions.


REFERENCES

  1. Lozano AR, Escamailla JA, Escobedo J, López-Cervantes M. Tendencia de la mortalidad por cardiopatía isquémica en México de 1950 a 1985. Salud Pública de México 1990; 32: 405.

  2. Secretaría de Salud y Dirección General de Estadística e Informática. Mortalidad 1996. México 1997: 69.

  3. Gillum RF. Epidemiology of Stroke in Hispanic Americans. Stroke 1995; 26(9): 1707-1712.

  4. Nicholls ES, Peruga A, Restreppo HE. Cardiovascular disease mortality in the Americas. World Health Stat Q 1993; 46(2): 134-150.

  5. The WHO Monica project geographic variations in the major risk factors for coronary heart disease in men and women aged 36-64 years. World Health Stat 1988; 41: 115-120.

  6. Winkleby MA, Gardner CHD, Taylor CB. The influence of gender and socio-economic factors on hispanic/white differences in body mass index. Preventive Medicine 1996; 25(2): 203-211.

  7. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334(6): 374-381.

  8. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Amer Med Assoc 1986; 256(20): 2823-2828.

  9. Leslie RD. United Kingdom Prospective Diabetes Study (UKPDS): what now or so what? Diabetes Metab Res Rev 1999; 15(1): 65-71.

  10. Florkowski CM, Scott RS. Type 2 diabetes towards the new millennium-the relative importance of glycaemic versus lipid control. Aust N Z J Med 1999; 29(2): 249-253.

  11. Kolanowski J. Obesity and hypertension: from pathophysiology to treatment. Int J Obes Relat Metab Disord 1999; 23: 42-46.

  12. González VC, Stern MP. La obesidad como factor de riesgo cardiovascular en México. Estudio en población abierta. Rev In Clín 1993; 45(1):13-21.

  13. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull 1997; 53(2): 238-252.

  14. Fanghänel G, Sánchez-Reyes L, Arellano MS, Valdés LE, Chavira LJ, Rascón PR. Prevalencia de factores de riesgo de enfermedad coronaria en trabajadores del Hospital General de México. Salud Pública de México 1997; 39: 427-432.

  15. Manson JE, Willet WC, Stampfer MJ. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685.

  16. Secretaría de Salud y Dirección General de Estadística e Informática. Mortalidad 1996. México 1997: 69.

  17. World Health Organization. Physical Status: The use and interpretation of anthropometry. WHO Technical Report Series. Geneva, WHO 1995: 329.

  18. Han TS. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br Med J 1995; 311: 1401-1405.

  19. Lara GJJ, Ávila RH. Concepto, definición y diagnóstico de la obesidad. En: Obesidad en México. Ed. Vargas AL, Bastarrachea SR, Laviada MH, González BJ, Ávila RH. Universidad Autónoma de Yucatán y Fundación Mexicana para la Salud editores 1999: 25-42.

  20. Joint National Committee on detection, evaluation and treatment of high blood pressure. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (INCV). Arch Intern Med 1993; 153: 154-183.

  21. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneve, (Technical Report Series, No. 854) World Health Organization, 1995: 368-369.

  22. Arroyo P, Loria A, Fernández V, Flegal KM, Kuri-Morales P, Olaiz G, Tapia-Conyer R. Prevalence of pre-obesity and obesity in urban adult Mexicans in comparison with other large surveys. Obesity Research 2000; 8(2): 179-185.

  23. Okosun IS, Prewitt TE, Cooper RS. Abdominal obesity in the United States: prevalence and attributable risk of hypertension. J Hum Hypertens 1999; 7(5): 424-430.

  24. Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999; 14(7): 39-58.

  25. Gartside PS, Wang P, Glueck CJ. Prospective assessment of coronary heart disease risk factors: the NHANES I epidemiologic follow-up study (NHEFS) 16-year follow-up. J Am Coll Nutr 1998; 17(3): 263-269.

  26. Gillum RF. Coronary heart disease, stroke, and hypertension in U.S. National Cohort: the NHANES I epidemiologic follow-up study. National Health and Nutrition Examination Survey. Ann Epidemiol 1996; 6: 259-262.

  27. Fanghänel G, Sánchez-Reyes L, López AJC, González-Barranco J. El colesterol total tiene un comportamiento en forma de U invertida de acuerdo al grado de obesidad y es independiente de la edad. XXXVIII Reunión Anual de la Sociedad Mexicana de Nutrición y Endocrinología. Resumen 61, Morelia, Michoacán 1998.

  28. Cueto L, Brito E, Barrera J, Gutiérrez M. Prevalencia de arterosclerosis coronaria. Prevalencia de factores de riesgo en burócratas de la ciudad de México, D F. Arch Inst Cardiol Mex 1989; 59: 19.

  29. Fanghänel G, Padilla RJ, Sánchez-Reyes L, Torres AE, Cortinas LL, Espinosa CJ. Prevalence of coronary artery disease risk factors in workers at the general Hospital of Mexico of the ministry of health. Endocrine Practice 1997; 3: 313-319.

  30. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to common amino acid polymorphism in the cholesterol ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998; 39(5): 1071-1078.

  31. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992;152(1):28-34.

  32. Connelly PW, Petrasovits A, Stachenko S, MacLean DR, Little JA, Chockalingam A. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group. Can J Cardiol 1999: 4: 428-433.

  33. González VC, Stern MP. La obesidad como factor de riesgo cardiovascular en México. Estudio en población abierta. Rev Invest Clin 1993; 45: 13-21.

  34. Krankenberg H, Lauer B, Schuler G. Diabetes and coronary heart disease. N Engl J Med 1998; 339(23): 1715-1716.

  35. Feher MD, Ellkeles RS. Lipid modification and coronary Heart disease in type 2 diabetes: different from the general population? Heart 1999; 81(1): 10-11.

  36. Van Berkel TF, Boersma H, Roos-Hesselink JW, Erdman RA, Simoons ML. Impact of smoking cessation and smoking interventions in patients with coronary heart disease. Eur Heart J 1999: 20(24): 1773-1782.

  37. Jacobs EJ, Thun MJ, Apicella LF. Cigar smoking and death from coronary heart disease in a prospective study of US men. Arch Intern Med 1999: 8;159(20): 2413-2418.

  38. De Padua Mansur A, Caramelli B, Vianna CB, Chamone D, Ramires JA. Smoking and lipoprotein abnormalities on platelet aggregation in coronary heart disease. Int J Cardiol 1997; 20;62(2): 151-154.




2020     |     www.medigraphic.com